Stock analysts at StockNews.com initiated coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a report issued on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright dropped their price objective on shares of Regulus Therapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, April 21st.
Regulus Therapeutics Stock Down 11.2 %
Shares of RGLS stock opened at $1.55 on Tuesday. The stock has a market cap of $30.19 million, a price-to-earnings ratio of -0.85 and a beta of 1.56. Regulus Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $3.40. The firm’s 50 day moving average price is $1.18 and its two-hundred day moving average price is $1.37.
Institutional Trading of Regulus Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Regulus Therapeutics by 108.5% in the third quarter. BlackRock Inc. now owns 45,614 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 23,738 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in Regulus Therapeutics by 52.3% during the third quarter. Commonwealth Equity Services LLC now owns 33,500 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 11,500 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Regulus Therapeutics during the third quarter valued at $54,000. Renaissance Technologies LLC increased its stake in Regulus Therapeutics by 498.2% during the first quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 111,100 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Regulus Therapeutics by 42.9% during the first quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 50,518 shares during the last quarter. Institutional investors own 55.47% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
- Get a free copy of the StockNews.com research report on Regulus Therapeutics (RGLS)
- FREYR Battery Is An Interesting Play On EVs: At Rock Bottom
- Analysts Upgrade GXO Logistics, Its First Quarter Says It All
- The Bottom Is In For AppLovin; Reversal Is Next
- Exact Sciences Serves Investors Exactly What They Wished For
- Shockwave Medical, Fast Grower, In Boston Scientific’s Sights?
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.